JOP20210295A1 - أشكال صلبة لمثبط GlyT1 - Google Patents
أشكال صلبة لمثبط GlyT1Info
- Publication number
- JOP20210295A1 JOP20210295A1 JOP/2021/0295A JOP20210295A JOP20210295A1 JO P20210295 A1 JOP20210295 A1 JO P20210295A1 JO P20210295 A JOP20210295 A JO P20210295A JO P20210295 A1 JOP20210295 A1 JO P20210295A1
- Authority
- JO
- Jordan
- Prior art keywords
- solid forms
- inhibitor
- glyt1 inhibitor
- glyt1
- glycine transporter
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 229940123454 Glucose transporter 1 inhibitor Drugs 0.000 title 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 3
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 | |
| PCT/US2020/030580 WO2020223419A1 (en) | 2019-05-01 | 2020-04-30 | Solid forms of a glyt1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210295A1 true JOP20210295A1 (ar) | 2023-01-30 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0295A JOP20210295A1 (ar) | 2019-05-01 | 2020-04-30 | أشكال صلبة لمثبط GlyT1 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (https=) |
| EP (1) | EP3962911A1 (https=) |
| JP (2) | JP7513349B2 (https=) |
| KR (1) | KR20220004174A (https=) |
| CN (1) | CN113784966B (https=) |
| AR (1) | AR118839A1 (https=) |
| AU (1) | AU2020266566B2 (https=) |
| BR (1) | BR112021020883A2 (https=) |
| CA (1) | CA3138288A1 (https=) |
| CL (2) | CL2021002837A1 (https=) |
| CO (1) | CO2021014260A2 (https=) |
| CR (1) | CR20210545A (https=) |
| DO (1) | DOP2021000224A (https=) |
| EA (1) | EA202192925A1 (https=) |
| EC (1) | ECSP21082195A (https=) |
| IL (1) | IL287630A (https=) |
| JO (1) | JOP20210295A1 (https=) |
| MA (1) | MA55801A (https=) |
| MX (1) | MX2021013341A (https=) |
| PE (1) | PE20212263A1 (https=) |
| PH (1) | PH12021552741A1 (https=) |
| SG (1) | SG11202111972YA (https=) |
| TW (1) | TW202106680A (https=) |
| UA (1) | UA129159C2 (https=) |
| WO (1) | WO2020223419A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| EA202192925A1 (ru) * | 2019-05-01 | 2022-03-23 | Бёрингер Ингельхайм Интернациональ Гмбх | Твердые формы ингибитора glyt1 |
| US11813257B2 (en) | 2020-01-09 | 2023-11-14 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| MX2023001818A (es) * | 2020-08-13 | 2023-03-13 | Boehringer Ingelheim Int | Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia. |
| IL301829A (en) | 2020-10-13 | 2023-06-01 | Boehringer Ingelheim Int | Process of reworking |
| WO2025140479A1 (zh) * | 2023-12-29 | 2025-07-03 | 苏州科睿思制药有限公司 | Iclepertin的晶型及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| RS20060190A (sr) * | 2003-10-14 | 2008-08-07 | Pfizer Products Inc., | Biciklični /3.1.0/ derivati kao inhibitori transportera glicina |
| CA2745690A1 (en) * | 2008-12-04 | 2010-06-10 | Evgeny Zlotinikov | Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| EP2381941A4 (en) * | 2008-12-29 | 2012-08-01 | Univ Vanderbilt | 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US9012489B2 (en) | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| IL270155B (en) * | 2017-04-27 | 2022-07-01 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| EA202192925A1 (ru) * | 2019-05-01 | 2022-03-23 | Бёрингер Ингельхайм Интернациональ Гмбх | Твердые формы ингибитора glyt1 |
| MX2023001818A (es) * | 2020-08-13 | 2023-03-13 | Boehringer Ingelheim Int | Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia. |
| IL301829A (en) * | 2020-10-13 | 2023-06-01 | Boehringer Ingelheim Int | Process of reworking |
-
2020
- 2020-04-30 EA EA202192925A patent/EA202192925A1/ru unknown
- 2020-04-30 TW TW109114685A patent/TW202106680A/zh unknown
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/es unknown
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/en active Pending
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/en not_active Ceased
- 2020-04-30 AU AU2020266566A patent/AU2020266566B2/en active Active
- 2020-04-30 PH PH1/2021/552741A patent/PH12021552741A1/en unknown
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/ko not_active Ceased
- 2020-04-30 UA UAA202106566A patent/UA129159C2/uk unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/en active Pending
- 2020-04-30 JP JP2021563717A patent/JP7513349B2/ja active Active
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/ar unknown
- 2020-04-30 CN CN202080032902.7A patent/CN113784966B/zh active Active
- 2020-04-30 CR CR20210545A patent/CR20210545A/es unknown
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/pt unknown
- 2020-04-30 AR ARP200101242A patent/AR118839A1/es unknown
- 2020-04-30 MA MA055801A patent/MA55801A/fr unknown
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/es unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/es unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/es unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/es unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en not_active Abandoned
-
2024
- 2024-03-21 CL CL2024000829A patent/CL2024000829A1/es unknown
- 2024-05-02 JP JP2024074707A patent/JP7714727B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552741A1 (en) | Solid forms of a glyt1 inhibitor | |
| PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
| MY202765A (en) | Triesters of cyclohexanetripropionic acid | |
| MX2022000397A (es) | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| EA201890767A1 (ru) | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений | |
| PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| GEP20217318B (en) | Pyrazole magl inhibitors | |
| ZA202103228B (en) | Crystal forms of an alk2 inhibitor | |
| MX2022000742A (es) | Metodo para disminuir los efectos adversos del interferon. | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
| WO2020009675A3 (en) | Solid oral pharmaceutical compositions of linagliptin | |
| MX370065B (es) | Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. | |
| MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| WO2017106798A3 (en) | Compositions and methods for treating gluten intolerance and disorders arising therefrom | |
| WO2019151965A3 (en) | Solid oral pharmaceutical compositions comprising apixaban | |
| EA202090432A1 (ru) | Новые соединения, активирующие путь nrf2 | |
| AU2017247612A9 (en) | Hafnia alvei based pharmaceutical and food compositions for inducing satiation and prolonging satiety | |
| PH12021552079A1 (en) | Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases |